参麦注射液的临床应用情况及不良反应分析

王明昭1 ，齐武强2

（1.陕西中医药大学附属医院，陕西 咸阳，712000；2.宝鸡市中医医院，陕西 宝鸡，721000）

浏览次数：263次 下载次数：388次

摘要：

目的 分析参麦注射液的临床应用及不良反应发生情况。方法 选择我院给予参麦注射液治疗的住院患者470例，对所有患者的临床资料进行回顾性分析，总结该类药物的临床应用与不良反应发生情况。结果 使用参麦注射液的470患者中， 以51～88岁的老年患者居多，占比80.21%；科室以肿瘤科为主，占比37.02%；药物使用时间主要为4～10 d 和11～20 d，占比 分别为48.51%与34.04%。470例患者的药物不良反应发生率为2.98%，均未进行特殊处理，停止用药后自行缓解。结论 我院参麦注射液的使用以老年患者和肿瘤科患者为主，参麦注射液的不良反应发生率总体较低，但临床上仍应加强参麦注射液不良反应情况的分析及监测，保证用药安全性。

关键词：不良反应；参麦注射液；应用情况

中图分类号：R286文献标志码：A文章编号：2096-1413(2017)28-0102-02

Clinical application and adverse reaction analysis of Shenmai injection
WANG Ming-zhao 1, QI Wu-qiang 2
(1. Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000; 2. Traditional Chinese Medicine
Hospital of Baoji, Baoji 721000, China)

ABSTRACT: Objective To analyze the clinical application and adverse reactions of Shenmai injection. Methods A total of 470 cases of hospitalized patients treated with Shenmai injection in our hospital were selected, and the clinical data of all the patients were analyzed retrospectively, the clinical application and adverse reactions of Shenmai injection were summarized. Results In 470 cases of hospitalized patients, the majority were 51 ~88 year old patients, accounted for 80.21%; the mainly department was oncology, accounted for 37.02%. Drug use time was mainly 4~10 d and 11~20 d, accounted for 48.51% and 34.04% respectively. The incidence of adverse drug reactions in the 470 patients was 2.98%, and no special treatment was performed, the adverse drug reactions were relieved after stopping medication. Conclusion The use of Shenmai injection in our hospital was mainly based on elderly patients and oncology patients, and the incidence of adverse reactions was generally low. However, the analysis and monitoring of adverse reactions of Shenmai injection should be strengthened to ensure the safety of drug use.
KEYWORDS: adverse reactions; Shenmai injection; application situation

参考文献：
[1] 朱玲琦,周昕,杜蕾,等.我院参麦注射液应用情况及不良反应分析 [J].中国药物警戒,2013,10(2):111-114.
[2] 崔英子,高宏伟,王泽玉,等.参麦注射液在心内科合理应用及不良 反应回顾性研究[J].长春中医药大学学报,2013,29(3):527-528.
[3] 冯志英,齐延伟,刘宝良,等.瑞通立联合参麦注射液在心肌梗死中 的应用观察[J].中国医药指南,2016,14(22):40-41.
[4] 庄海峰,张宇,蔡皎皓,等.右丙亚胺联合参麦注射液降低蒽环类药 物心脏毒性的临床研究[J].中国肿瘤临床,2012,39(6):348-351.
[5] 丁峰,石庆平,姜晓东,等.Logistic 模型和ROC 曲线对参麦注射液 致不良反应的预测分析[J].中国中药杂志,2015,40(7):1404-1409.
[6] 屠旦来.54 例参麦注射液导致过敏性休克不良反应报告分析[J]. 中国现代药物应用,2013,7(22):21-22.
[7] 苏军,刘春富.阿托伐他汀和参麦注射液对冠心病慢性心力衰竭的 疗效以及安全性分析[J].中国医药指南,2012,10(22):220-221.
[8] 姜青君.参麦注射液在心内科合理应用及不良反应回顾性研究[J]. 中西医结合心血管病电子杂志,2015,3(34):68.